A legal analysis highlighted how healthcare AI developers face conflicting requirements across patent strategy, FDA enforcement realities, and HIPAA privacy constraints. The piece argues that teams need to design compliance into AI products early, because patent claims, regulatory pathways, and data-handling rules can’t be optimized independently. The focus for biotech and health tech is practical: how to structure evidence generation and data provenance when regulatory review and patient privacy standards limit what can be shared or reused. It also underscores that “defensibility” in AI will depend on mapping legal regimes to technical workflows. For companies building AI tools around medical or clinical datasets, the article frames preparedness as the differentiator between deployable products and ones that stall in governance reviews.